In this study, we were able to show, that age, sex, co-morbidities, risk factors as well as the vast majority of neurological diseases, especially the classical “stroke mimics” do not critically interfere with the use of GFAP as an ICH biomarker. This evidence concerns the gene GFAP and nervous system disorder.